Please assess the completion status of the following clinical trial:

Trial Title: Copanlisib Chinese PK Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand and to sign an informed consent form. The informed consent must be signed before any study specific tests or procedures are done~* Chinese, age ≥ 18 years~* Patients with histologically confirmed indolent NHL (excluding chronic lymphocytic leukemia) that have relapsed and who are without past or current central nervous system involvement.~* Patients must have at least 1 measurable lesion according to the Lugano Classification.~  * Patients affected by LPL/WM must have also measurable disease, defined as presence of IgM paraprotein with a minimum IgM level of equal to or greater than 2 times the upper limit of normal (ULN) OR over 10% of lymphoplasmacytic cells in bone marrow.~ * Patients with splenic MZL with splenomegaly but no measurable lesion will be considered eligible.~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~* Life expectancy of at least 12 weeks~* Left ventricular ejection fraction (LVEF) ≥ 50%~* Prothrombin time (PT) or international normalized ratio (INR) and activated partial thromboplastin time (aPTT) \< 1.5 x the upper limit of normal (ULN)~* Adequate bone marrow, liver and renal function~* Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment~* Women of childbearing potential and men must agree to use highly effective contraception from signing of the informed consent form until at least 1 month after the last study drug administration. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1% per year), e.g. hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner and sexual abstinence~Exclusion Criteria:~Medical and surgical history:~* Uncontrolled hypertension (Blood pressure ≥ 150/90 mmHg despite optimal medical management)~* Proteinuria of CTCAE grade 3 or higher (\> 3.5 g/24 h, measured by urine protein: creatinine ratio on a random urine sample)~* Known bleeding diathesis. Any hemorrhage or bleeding event ≥ Grade 3 within 28 days of start of study medication. (NCI-CTCAE Version 4.03)~* Uncontrolled diabetes with HbA1c ≥ 8.5%~* Ongoing cytomegalovirus (CMV) infection as confirmed by positive polymerase chain reaction (PCR) for CMV~Excluded previous therapies and medications:~* Prior treatment with PI3K inhibitors~* Anticancer chemotherapy or immunotherapy during the study or within 28 days of first study treatment.~* Patients must have recovered from the toxic effects (Grade \<2) of the previous anti-cancer chemotherapy or immunotherapy (with the exception of alopecia)~* Biological response modifiers, such as Granulocyte colony stimulating factor (GCSF) within 14 days of first study treatment. G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the principal investigator; however they may not be substituted for a required dose reduction~* Use of strong inhibitors of CYP3A4 is prohibited from Day -14 and for the duration of the study~* Use of St John's Wort or strong inducers of CYP3A4 is prohibited from Day -14 and for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Copanlisib (Aliqopa, BAY80-6946) (Type: EXPERIMENTAL): Planned at least 12 patients who meet the entry criteria will receive 60 mg copanlisib as single agent, with dosing on Days 1, 8 and 15 of each 28-day treatment cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).